EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics

Setyo Teguh Waluyo, Brahmana Askandar Tjokroprawiro, Anny Setijo Rahaju

Cancer Treatment and Research Communications · 2023

DOI: 10.1016/j.ctarc.2023.100766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Setyo Teguh Waluyo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Subspecialist Education Program, Dr Soetomo General Academic Hospital, Med…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Endometrial Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study aimed to determine the association of estrogen receptor (ER) and programmed death ligand-1 (PD-L1) expression with the clinicopathological characteristics of type 1 endometrial cancer. MATERIALS AND METHODS: A total of 85 patients with type 1 endometrial cancer who underwent surgery at the Dr. Soetomo Hospital, Surabaya, Indonesia were retrospectively studied. Data about the age, menopausal status, body mass index, disease stage, cell differentiation, angiolymphatic invasion, myometrial invasion, and adjuvant therapy of the patients were collected from medical records. Immunohistochemistry with ER and PD-L1 antibodies was performed on all samples. The association between ER and PD-L1 expression and clinicopathological characteristics was statistically analyzed. RESULTS: The positivity rates of ER and PD-L1 in type 1 endometrial cancer were 68.2 % and 78.5 %, respectively. ER positivity was significantly correlated with body mass index (BMI) ≥25, premenopausal status, early stage of disease,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenEndometrial NeoplasmsFemaleHumansMiddle AgedLigandsReceptors, EstrogenRetrospective StudiesEstrogen Receptor alpha

Stichwörter der Autor:innen

ClinicopathologyEndometrial cancerEstrogen receptorPD-L1 expression

Substanzen

B7-H1 AntigenLigandsReceptors, EstrogenCD274 protein, humanESR1 protein, humanEstrogen Receptor alpha

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Subspecialist Education Program, Dr Soetomo General Academic Hospital, Medical Faculty - Universitas Airlangga, Surabaya, Indonesia.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Electronic address: brahmanaaskandar@fk.u…
  • Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital/Universitas Airlangga Hospital, Surabaya, Indonesia.

Zitieren

APA

Waluyo, S. T., Tjokroprawiro, B. A., & Rahaju, A. S. (2023). Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100766

Vancouver

Waluyo ST, Tjokroprawiro BA, Rahaju AS. Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics. Cancer Treatment and Research Communications. 2023. doi:10.1016/j.ctarc.2023.100766

BibTeX
@article{Waluyo2023,
  author = {Waluyo, Setyo Teguh and Tjokroprawiro, Brahmana Askandar and Rahaju, Anny Setijo},
  title = {Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics},
  journal = {Cancer Treatment and Research Communications},
  year = {2023},
  doi = {10.1016/j.ctarc.2023.100766}
}
Kostenlos starten →